Literature DB >> 18349061

Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.

Dennis M Black1, Mary L Bouxsein, Lisa Palermo, Joan A McGowan, David C Newitt, Eyal Rosen, Sharmila Majumdar, Clifford J Rosen.   

Abstract

CONTEXT: Daily PTH administration increases bone mineral density (BMD) and reduces fracture risk. However, cost and compliance significantly limit clinical use.
OBJECTIVE: Our objective was to determine whether less frequent PTH administration increases lumbar spine BMD. PARTICIPANTS, DESIGN, AND
SETTING: Fifty postmenopausal women ages 45-70 yr with femoral neck BMD T-score between -1.0 and -2.0 participated in a double-blind, randomized, placebo-controlled trial at St. Joseph Hospital, Bangor, ME. INTERVENTION: Subjects received sc injections of daily PTH(1-84) (100 mug) or placebo for 1 month, followed by weekly injections (PTH or placebo) for 11 months. OUTCOMES: Change in lumbar spine dual-energy x-ray absorptiometry areal BMD (primary) was assessed. Secondary outcomes included volumetric BMD at spine and hip by quantitative computed tomography, trabecular bone microarchitecture by magnetic resonance imaging of distal radius, and biochemical bone turnover markers.
RESULTS: At 12 months, lumbar spine areal BMD increased 2.1% in PTH-treated women compared with placebo (P = 0.03). Vertebral trabecular volumetric BMD increased 3.8% in PTH-treated women compared with placebo group (P = 0.08). PTH-treated women also had higher distal radial trabecular bone volume, number, and thickness compared with placebo-treated women (P < 0.04). After 1 month of daily PTH, N-terminal propeptide of type I collagen (P1NP) was markedly increased compared with placebo (P < 0 .0001), and a difference persisted, although lessened, throughout the study. Bone resorption indices were unchanged in PTH-treated women and were reduced in the placebo group.
CONCLUSION: Once-weekly PTH after 1 month of daily treatment increases spine BMD, radial trabecular bone, and bone formation markers in postmenopausal women. These results suggest that less frequent alternatives to daily PTH dosing for 2 yr could be effective. Additional studies are required to define the optimal frequency of PTH administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349061      PMCID: PMC2435646          DOI: 10.1210/jc.2007-2781

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Processing and analysis of in vivo high-resolution MR images of trabecular bone for longitudinal studies: reproducibility of structural measures and micro-finite element analysis derived mechanical properties.

Authors:  D C Newitt; B van Rietbergen; S Majumdar
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

2.  Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Authors:  Clifford J Rosen; Marc C Hochberg; Sydney L Bonnick; Michael McClung; Paul Miller; Susan Broy; Risa Kagan; Erluo Chen; Richard A Petruschke; Desmond E Thompson; Anne E de Papp
Journal:  J Bone Miner Res       Date:  2004-09-29       Impact factor: 6.741

3.  Assessment of vertebral bone mineral density using volumetric quantitative CT.

Authors:  T F Lang; J Li; S T Harris; H K Genant
Journal:  J Comput Assist Tomogr       Date:  1999 Jan-Feb       Impact factor: 1.826

4.  Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels.

Authors:  T Fujita; T Inoue; H Morii; R Morita; H Norimatsu; H Orimo; H E Takahashi; K Yamamoto; M Fukunaga
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

9.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

10.  Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography.

Authors:  A Laib; P Rüegsegger
Journal:  Bone       Date:  1999-01       Impact factor: 4.398

View more
  20 in total

1.  PTHrP 1-141 and 1-86 increase in vitro bone formation.

Authors:  Blake Eason Hildreth; Jillian L Werbeck; Nandu K Thudi; Xiyun Deng; Thomas J Rosol; Ramiro E Toribio
Journal:  J Surg Res       Date:  2010-03-16       Impact factor: 2.192

2.  The effect of bisphosphonate and intermittent human parathyroid hormone 1-34 treatments on cortical bone allografts in rabbits.

Authors:  Y Yamamoto; Y Washimi; A Kanaji; K Tajima; D Ishimura; H Yamada
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

3.  Repetition of continuous PTH treatments followed by periodic withdrawals exerts anabolic effects on rat bone.

Authors:  Masaya Etoh; Akira Yamaguchi
Journal:  J Bone Miner Metab       Date:  2010-11       Impact factor: 2.626

4.  Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men.

Authors:  Jean-Pierre Devogelaer; Yves Boutsen; Daniel H Manicourt
Journal:  Curr Osteoporos Rep       Date:  2010-09       Impact factor: 5.096

5.  Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women.

Authors:  Elaine W Yu; Robert M Neer; Hang Lee; Jason J Wyland; Amanda V de la Paz; Melissa C Davis; Makoto Okazaki; Joel S Finkelstein
Journal:  Bone       Date:  2010-11-24       Impact factor: 4.398

Review 6.  Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.

Authors:  Donovan Tay; Serge Cremers; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

7.  Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism.

Authors:  M R Rubin; J S Manavalan; D W Dempster; J Shah; S Cremers; S Kousteni; H Zhou; D J McMahon; A Kode; J Sliney; E Shane; S J Silverberg; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2010-09-29       Impact factor: 5.958

Review 8.  MRI assessment of bone structure and microarchitecture.

Authors:  Gregory Chang; Sean Boone; Dimitri Martel; Chamith S Rajapakse; Robert S Hallyburton; Mitch Valko; Stephen Honig; Ravinder R Regatte
Journal:  J Magn Reson Imaging       Date:  2017-02-06       Impact factor: 4.813

9.  Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis.

Authors:  Luca Pietrogrande
Journal:  Int J Womens Health       Date:  2010-08-09

10.  Peritoneal dialysis can alleviate the clinical course of hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.

Authors:  Guang Yang; Yifei Ge; Xiaoming Zha; Huijuan Mao; Ningning Wang; Changying Xing
Journal:  Int Urol Nephrol       Date:  2019-01-28       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.